Cargando…

Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles

Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Daichen, Yang, Xiaofan, Chen, Yanfei, Hu, Pingping, Zhang, Yingying, Zhang, Yan, Liang, Ning, Xie, Jian, Qiao, Lili, Deng, Guodong, Chen, Fangjie, Zhang, Jiandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579911/
https://www.ncbi.nlm.nih.gov/pubmed/37854883
http://dx.doi.org/10.3389/fbioe.2023.1286502
_version_ 1785121833410887680
author Song, Daichen
Yang, Xiaofan
Chen, Yanfei
Hu, Pingping
Zhang, Yingying
Zhang, Yan
Liang, Ning
Xie, Jian
Qiao, Lili
Deng, Guodong
Chen, Fangjie
Zhang, Jiandong
author_facet Song, Daichen
Yang, Xiaofan
Chen, Yanfei
Hu, Pingping
Zhang, Yingying
Zhang, Yan
Liang, Ning
Xie, Jian
Qiao, Lili
Deng, Guodong
Chen, Fangjie
Zhang, Jiandong
author_sort Song, Daichen
collection PubMed
description Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these challenges and provide more effective and safer options for cancer patients. In recent years, the use of live bacteria, engineered bacteria, or bacterial derivatives to deliver antitumor drugs to specific tumor sites for controlled release has emerged as a promising therapeutic tool. This approach offers several advantages over traditional cancer therapies, including targeted drug delivery and reduced toxicity to healthy tissues. Ongoing research in this field holds great potential for further developing more efficient and personalized cancer therapies, such as E. coli, Salmonella, Listeria, and bacterial derivatives like outer membrane vesicles (OMVs), which can serve as vehicles for drugs, therapeutic proteins, or antigens. In this review, we describe the advances, challenges, and future directions of research on using live bacteria or OMVs as carriers or components derived from bacteria of delivery systems for cancer therapy.
format Online
Article
Text
id pubmed-10579911
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105799112023-10-18 Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles Song, Daichen Yang, Xiaofan Chen, Yanfei Hu, Pingping Zhang, Yingying Zhang, Yan Liang, Ning Xie, Jian Qiao, Lili Deng, Guodong Chen, Fangjie Zhang, Jiandong Front Bioeng Biotechnol Bioengineering and Biotechnology Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these challenges and provide more effective and safer options for cancer patients. In recent years, the use of live bacteria, engineered bacteria, or bacterial derivatives to deliver antitumor drugs to specific tumor sites for controlled release has emerged as a promising therapeutic tool. This approach offers several advantages over traditional cancer therapies, including targeted drug delivery and reduced toxicity to healthy tissues. Ongoing research in this field holds great potential for further developing more efficient and personalized cancer therapies, such as E. coli, Salmonella, Listeria, and bacterial derivatives like outer membrane vesicles (OMVs), which can serve as vehicles for drugs, therapeutic proteins, or antigens. In this review, we describe the advances, challenges, and future directions of research on using live bacteria or OMVs as carriers or components derived from bacteria of delivery systems for cancer therapy. Frontiers Media S.A. 2023-10-03 /pmc/articles/PMC10579911/ /pubmed/37854883 http://dx.doi.org/10.3389/fbioe.2023.1286502 Text en Copyright © 2023 Song, Yang, Chen, Hu, Zhang, Zhang, Liang, Xie, Qiao, Deng, Chen and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Song, Daichen
Yang, Xiaofan
Chen, Yanfei
Hu, Pingping
Zhang, Yingying
Zhang, Yan
Liang, Ning
Xie, Jian
Qiao, Lili
Deng, Guodong
Chen, Fangjie
Zhang, Jiandong
Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
title Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
title_full Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
title_fullStr Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
title_full_unstemmed Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
title_short Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
title_sort advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579911/
https://www.ncbi.nlm.nih.gov/pubmed/37854883
http://dx.doi.org/10.3389/fbioe.2023.1286502
work_keys_str_mv AT songdaichen advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT yangxiaofan advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT chenyanfei advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT hupingping advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT zhangyingying advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT zhangyan advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT liangning advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT xiejian advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT qiaolili advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT dengguodong advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT chenfangjie advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles
AT zhangjiandong advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles